Changes in FXR1 expression after Chemotherapy for Rhabdomyosarcoma
- 1 June 2021
- journal article
- research article
- Published by Elsevier in Journal of Pediatric Surgery
- Vol. 56 (6) , 1148-1156
Abstract
No abstract availableKeywords
Funding Information
- Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center
- National Center for Advancing Translational Sciences
This publication has 33 references indexed in Scilit:
- A Novel Role for the RNA–Binding Protein FXR1P in Myoblasts Cell-Cycle Progression by Modulating p21/Cdkn1a/Cip1/Waf1 mRNA StabilityPLOS Genetics, 2013
- PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk StratificationJournal of Clinical Oncology, 2012
- Race Disparities in Wilms Tumor Incidence and BiologyJournal of Surgical Research, 2011
- Genome-Wide Identification of PAX3-FKHR Binding Sites in Rhabdomyosarcoma Reveals Candidate Target Genes Important for Development and CancerCancer Research, 2010
- Fragile X protein family member FXR1P is regulated by microRNAsRNA, 2010
- Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975‐2005Cancer, 2009
- PAX3–FOXO1 fusion gene in rhabdomyosarcomaCancer Letters, 2008
- Identification of a PAX-FKHR Gene Expression Signature that Defines Molecular Classes and Determines the Prognosis of Alveolar RhabdomyosarcomasCancer Research, 2006
- Are Myogenin and MyoD1 Expression Specific for Rhabdomyosarcoma?American Journal of Surgical Pathology, 2001
- The fragile X mental retardation protein is associated with ribosomesNature Genetics, 1996